AU1877700A - Treatment of conditions with a need for the inhibition of gsk-3 - Google Patents

Treatment of conditions with a need for the inhibition of gsk-3

Info

Publication number
AU1877700A
AU1877700A AU18777/00A AU1877700A AU1877700A AU 1877700 A AU1877700 A AU 1877700A AU 18777/00 A AU18777/00 A AU 18777/00A AU 1877700 A AU1877700 A AU 1877700A AU 1877700 A AU1877700 A AU 1877700A
Authority
AU
Australia
Prior art keywords
gsk
inhibition
treatment
conditions
need
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU18777/00A
Inventor
Matthew Paul Coghlan
Julie Caroline Holder
Alastair David Reith
David Glynn Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU1877700A publication Critical patent/AU1877700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
AU18777/00A 1998-12-23 1999-12-22 Treatment of conditions with a need for the inhibition of gsk-3 Abandoned AU1877700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9828640.4A GB9828640D0 (en) 1998-12-23 1998-12-23 Novel method and compounds
GB9828640 1998-12-23
PCT/GB1999/004374 WO2000038675A1 (en) 1998-12-23 1999-12-22 Treatment of conditions with a need for the inhibition of gsk-3

Publications (1)

Publication Number Publication Date
AU1877700A true AU1877700A (en) 2000-07-31

Family

ID=10845024

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18777/00A Abandoned AU1877700A (en) 1998-12-23 1999-12-22 Treatment of conditions with a need for the inhibition of gsk-3

Country Status (4)

Country Link
EP (1) EP1140070A1 (en)
AU (1) AU1877700A (en)
GB (1) GB9828640D0 (en)
WO (1) WO2000038675A1 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013916A1 (en) * 1999-08-20 2001-03-01 Sagami Chemical Research Center Drugs inhibiting cell death
EP1244461A2 (en) * 1999-12-23 2002-10-02 The Ontario Cancer Institute INHIBITION OF GSK-3$g(b)
ES2166328B1 (en) * 2000-05-11 2003-09-16 Consejo Superior Investigacion HETEROCICLIC INHIBITORS OF ENZYME GSK 3 USEFUL IN THE TREATMENT OF NEURODEGENERATIVE AND HYPERPROLIFERATIVE PROCESSES
IL152721A0 (en) * 2000-05-11 2003-06-24 Consejo Superior Investigacion Heterocyclic compounds and pharmaceutical compositions for inhibition of glycogen synthase kinase containing the same
EP1307447B1 (en) 2000-07-27 2004-12-15 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
EP1698627A1 (en) 2000-09-15 2006-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001296959A1 (en) * 2000-10-02 2002-04-15 Reddy Us Therapeutics, Inc Methods and compositions for the treatment of inflammatory diseases
PT1337527E (en) * 2000-11-07 2009-12-10 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
RU2275373C2 (en) 2000-12-08 2006-04-27 Орто-Макнейл Фармасьютикал, Инк. Macroheterocyclic compounds
ES2272567T3 (en) 2000-12-21 2007-05-01 Vertex Pharmaceuticals Incorporated PIRAZOL COMPOUNDS USED AS PROTEIN KINASE INHIBITORS.
GB0103031D0 (en) * 2001-02-07 2001-03-21 Smithkline Beecham Plc Novel treatment
AU2002259071A1 (en) 2001-04-30 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes
WO2003024447A1 (en) * 2001-09-20 2003-03-27 Smithkline Beecham Corporation Inhibitors of glycogen synthase kinase-3
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
WO2003049739A1 (en) 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
AU2003235798A1 (en) * 2002-01-10 2003-07-24 F. Hoffmann-La Roche Ag Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
MXPA04007697A (en) 2002-02-06 2004-11-10 Vertex Pharma Heteroaryl compounds useful as inhibitors of gsk-3.
EP1490093A4 (en) * 2002-03-01 2007-04-11 Novartis Vaccines & Diagnostic Methods and compositions for the treatment of ischemia
EP1483265B1 (en) 2002-03-05 2006-11-22 Eli Lilly And Company Purine derivatives as kinase inhibitors
MXPA04008671A (en) 2002-03-08 2004-12-06 Lilly Co Eli Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors.
US7125878B2 (en) 2002-05-08 2006-10-24 Janssen Pharmaceutica Substituted pyrroline kinase inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
JP2006514918A (en) * 2002-07-23 2006-05-18 スミスクライン ビーチャム コーポレーション Pyrazolopyrimidines as kinase inhibitors
WO2004013140A1 (en) 2002-08-02 2004-02-12 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
US7268136B2 (en) 2002-12-18 2007-09-11 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
EP1611132A1 (en) * 2003-03-27 2006-01-04 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
EP1645286A1 (en) * 2003-04-18 2006-04-12 Kyowa Hakko Kogyo Co., Ltd. Drug for nerve regeneration
CN1897950A (en) 2003-10-14 2007-01-17 惠氏公司 Fused-aryl and heteroaryl derivatives and methods of their use
WO2005086814A2 (en) * 2004-03-09 2005-09-22 The Uab Research Foundation Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3)
EP1751133B1 (en) 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
CN1949967B (en) * 2004-05-12 2012-02-01 拜尔作物科学有限公司 Plant growth regulation
EP1662259A1 (en) * 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
EP1819697B1 (en) 2004-12-08 2012-08-01 Johannes Gutenberg-Universität Mainz 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
CN101128212A (en) * 2005-01-18 2008-02-20 国立大学法人京都大学 Drugs for nerve cell regeneration
EP1885454A2 (en) 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
AR056763A1 (en) 2005-11-03 2007-10-24 Vertex Pharma AMINOPIRIMIDINES REPLACED WITH TIAZOL OR PIRAZOL, USEFUL AS ANTICANCER AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
PT2383271E (en) 2006-03-13 2013-10-10 Kyorin Seiyaku Kk Aminoquinolones as gsk-3 inhibitors
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2446269T3 (en) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranyl-4-indolyl-maleimides as potent inhibitors of GSK-3 for neurodegenerative disorders
MX2009008253A (en) 2007-01-31 2009-10-12 Vertex Pharma Kinase inhibitors.
JP5393489B2 (en) 2007-03-09 2014-01-22 バーテックス ファーマシューティカルズ インコーポレイテッド Aminopyrimidines useful as inhibitors of protein kinases
ES2400104T3 (en) 2007-07-31 2013-04-05 Vertex Pharmaceuticals Incorporated Process for preparation of 5-fluoro-1H-pyrazolo [3,4-b] pyridin-3-amine and derivatives thereof
US8389514B2 (en) 2007-09-11 2013-03-05 Kyorin Pharmaceutical Co., Ltd. Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
CN101855229A (en) 2007-09-12 2010-10-06 埃迪威克斯生物科学公司 Spirocyclic aminoquinolones as GSK-3 inhibitors
US20110184046A1 (en) 2008-07-11 2011-07-28 Dinah Wen-Yee Sah Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
WO2010027921A1 (en) 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
GB201111427D0 (en) * 2011-07-05 2011-08-17 Amakem Nv Novel bisindolylmaleimides, pan-pkc inhibitors
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
CN1093759C (en) * 1995-11-20 2002-11-06 伊莱利利公司 Protein kinase C inhibitor
AU2819397A (en) * 1996-05-07 1997-11-26 Presidents And Fellows Of Harvard College Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)

Also Published As

Publication number Publication date
GB9828640D0 (en) 1999-02-17
WO2000038675A1 (en) 2000-07-06
EP1140070A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
AU1877700A (en) Treatment of conditions with a need for the inhibition of gsk-3
AU2935200A (en) Compounds for the treatment of obesity
AU3180795A (en) Hydrate inhibition
HK1047284A1 (en) 2-amino-benzoxazinone derivatives for the treatment of obesity
ZA991578B (en) Compounds for the treatment of ischemia.
AU1772399A (en) Well treatment
AU5038299A (en) Process for the biocidal treatment of surfaces
AU3187595A (en) Compounds for the treatment of restenosis
GB9400538D0 (en) Hydrate inhibition
AU1142600A (en) Catheter
AU7750100A (en) Method for the treatment of obesity
AU2021601A (en) Composition for the treatment of dandruff
AU4369000A (en) Inhibition of complement action
AU3782495A (en) Sewage respiration inhibition
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
AU3119100A (en) Methods for the prevention and treatment of post-surgical complications
AU6277699A (en) Guarantee 20
AU1940800A (en) Combination therapy for the treatment of sepsis
AU6508298A (en) Fouling inhibition
AU4700197A (en) Corrosion inhibition
AUPP375198A0 (en) An anticorrosion treatment
AU6006099A (en) Preventives or remedies for cachexia
AU1277800A (en) Wood-screw or the like

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase